Quantcast
Last updated on April 23, 2014 at 11:18 EDT

Latest Mitral regurgitation Stories

2014-04-16 08:32:01

Funding Will Enable Initiation of Blinded, Randomized Clinical Trial and Expanded Commercialization of CARILLON® Mitral Contour System® KIRKLAND, Wash., April 16, 2014 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced the completion of a $20 million financing. M. H. Carnegie & Co. and Lumira Capital led the financing as part of an international syndicate of institutional investors from Australia, the U.S. and Canada. The financing follows the company's completion...

2014-04-09 16:26:11

ROSEVILLE, Minn., April 9, 2014 /PRNewswire/ -- Tendyne Holdings, Inc. ("Tendyne"), a privately held clinical stage medical device company developing technologies for transcatheter mitral valve replacement, announced today that it has secured $25 million in an oversubscribed Series C financing led by Apple Tree Partners, along with Boulle Group members and other existing investors. Proceeds will be used for validation of Tendyne's novel Transcatheter Mitral Valve Implant to treat...

2014-02-19 12:28:22

Sets Stage for Expanded Adoption Of CARILLON® Mitral Contour System® KIRKLAND, Wash., Feb. 19, 2014 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced that the Company's CARILLON(® )Mitral Contour System(® )has received German Neue Untersuchungs und Behandlungsmethoden (NUB) Status 1 approval across 120 leading hospitals in Germany, a decision from German regulators that may positively influence reimbursement from insurance companies for the costs of CARILLON...

2014-02-18 12:30:32

- Harpoon Has Raised More Than $300,000 in Competitive Grants and Award Funding in Less Than a Year - BALTIMORE, Feb. 18, 2014 /PRNewswire/ -- University of Maryland (UM) Ventures and Harpoon Medical, Inc. announced today that Harpoon Medical has obtained exclusive rights to a portfolio of technologies for cardiac valve repair from the University of Maryland, Baltimore (UMB). The licensed technology was developed in the Division of Cardiac Surgery at The University of Maryland School...

2013-12-19 12:28:48

Valve repair can improve the quality of life for patients with debilitating mitral valve disease HARRISBURG, Pa., Dec. 19, 2013 /PRNewswire-iReach/ -- Last week, Brijeshwar Maini, MD, Cardiologist and Director of Cardiovascular Research and Education at PinnacleHealth, and Mubashir Mumtaz, MD, Chief of Cardiothoracic Surgery at PinnacleHealth, performed the first catheter-based valve repair with the MitraClip® in Pennsylvania following the device's FDA approval. The U.S. Food and...

2013-11-19 23:02:53

New Findings by Research Team, Including Researchers from Icahn School of Medicine at Mount Sinai, Showing Mitral Valve Replacement May Be More Effective Than Mitral Valve Repair Reported at AHA Scientific Sessions 2013 and in New England Journal of Medicine New York, NY (PRWEB) November 19, 2013 The Cardiothoracic Surgical Trials Network (CTSN), whose Data and Clinical Coordinating Center is at Icahn School of Medicine at Mount Sinai, is reporting for the first time evidence on whether...

2013-11-13 08:28:46

TSX Venture Exchange: NVC VANCOUVER, Nov. 13, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that the first patent covering the company's innovative Tiara(TM) transcatheter mitral valve replacement technology has been issued by the US Patent and Trademark Office. The new patent protects key aspects of the Tiara mitral valve prosthesis. It is the first patent to issue from a portfolio of US and international patent applications Neovasc has filed aimed at...

2013-10-30 20:24:51

Results Show Treatment Provides Clinical Benefits and Improves Quality of Life for Patients with Debilitating Mitral Valve Disease Who Are at Prohibitive Surgical Risk ABBOTT PARK, Ill., Oct. 30, 2013 /PRNewswire/ -- Abbott today announced clinically meaningful changes to quality of life, a reduction in rehospitalization for heart failure, and functional improvements for patients treated with the company's first-in-class, catheter-based MitraClip(®) therapy for patients with degenerative...

2013-10-29 08:31:53

--Preclinical Studies Show Innovative Transcatheter Product to Treat Mitral Regurgitation is Safe, Technically Feasible and Results in a Well-Functioning Mitral Bioprosthesis- --Sets Stage for First-in-Human Implantations Targeted for Early 2014-- TSX Venture Exchange: NVC VANCOUVER, Oct. 29, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that a review of results from preclinical studies of its Tiara(TM)( )valve for the transcatheter treatment of mitral...

2013-10-28 04:20:55

MUNICH and PALO ALTO, California, October 28, 2013 /PRNewswire/ -- BioMedPartners and Edwards LifeSciences Join Series A in Second Closing Middle Peak Medical, a development-stage medical device company that will commercialize a novel technology for treating mitral valve disease, has raised an additional $3M in a second closing of its over-subscribed Series A financing, which now totals approximately $11M. Additional Series A investors include BioMedInvest II LP and...